CKW Financial Group Sells 592 Shares of Johnson & Johnson (NYSE:JNJ)

CKW Financial Group reduced its stake in Johnson & Johnson (NYSE:JNJ) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,141 shares of the company’s stock after selling 592 shares during the period. Johnson & Johnson comprises approximately 0.1% of CKW Financial Group’s investment portfolio, making the stock its 28th largest position. CKW Financial Group’s holdings in Johnson & Johnson were worth $599,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. McLean Asset Management Corp boosted its position in Johnson & Johnson by 6.2% in the fourth quarter. McLean Asset Management Corp now owns 3,390 shares of the company’s stock valued at $490,000 after buying an additional 198 shares in the last quarter. waypoint wealth counsel lifted its stake in shares of Johnson & Johnson by 4.0% in the 4th quarter. waypoint wealth counsel now owns 5,092 shares of the company’s stock valued at $736,000 after acquiring an additional 196 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $85,886,000. Apexium Financial LP grew its position in Johnson & Johnson by 108.1% during the 4th quarter. Apexium Financial LP now owns 21,679 shares of the company’s stock worth $3,135,000 after acquiring an additional 11,262 shares during the last quarter. Finally, Capital Asset Advisory Services LLC increased its holdings in Johnson & Johnson by 2.1% in the 4th quarter. Capital Asset Advisory Services LLC now owns 30,252 shares of the company’s stock worth $4,362,000 after purchasing an additional 631 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on JNJ shares. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Guggenheim boosted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Morgan Stanley lowered their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.44.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $152.78 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business has a 50-day simple moving average of $147.73 and a 200 day simple moving average of $156.10. The firm has a market capitalization of $367.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.